the game is ON, page-93

Not sure the industry average TO price should be applied to Neu.

Assuming that all x 4 2591 trials are successful (management themselves saying no deal until ph 2 complete), it has been noted on this forum the strategic structured ph 2 trails with PMS going first, and knowing that 2566 already a approved in the treatment for Rhetts and both Rhetts and Autism sharing common features, 2566 ability to reduce inflammation and promote brain cell growth, then 2591 potentially being far superior in all aspects.

I think we should be comparing any previous TO prices for multiple treatments in CNS, in Neu case potentially x 4 anything in that realm and with x 2 licensed out with $2bn minimum in revenue attached for a potential suitor or a comparable TO for a treatment in Autism?

If we are successful and the science is truly as good as some say then there is no way we are getting TO based on industry averages.